scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Qi Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tumor Microenvironment, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guizhou Provincial High Level Innovative Talent Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
The intricate origins, subsets, and characteristics of TCR (T Cell Receptor) s, along with the mechanisms underpinning the antitumor response of tumor-infiltrating T lymphocytes within the tumor microenvironment (TME) remain enigmatic. Recently, the advent of single-cell RNA+TCR-sequencing (scRNA+TCR seq) has revolutionized TME analysis, providing unprecedented insight into the origins, cell subsets, TCR CDR3 compositions, and the expression patterns of response/depletion factors within individual tumor-infiltrating T lymphocytes. Our analysis of the shared scRNA+TCR seq dataset revealed a substantial presence of dual TCR T cells, characterized by clonal hyperplasia and remarkable migratory prowess across various tissues, including blood, normal, peritumoral, and tumor tissues in non-small cell lung cancer patients. Notably, dual TCR CD8+T cells predominantly fell within the CXCL13+subset, displaying potent antitumor activity and a strong preference for tumor tissue residency. Conversely, dual TCR CD4+T cells were predominantly classified as CD5+ or LMNA+subsets, exhibiting a more even distribution across diverse tissue types. By harnessing scRNA+TCR seq and other cutting-edge technologies, we can delve deeper into the effects and mechanisms that regulate the antitumor response or tolerance of dual TCR T cells. This innovative approach holds immense promise in offering fresh perspectives and avenues for advancing research on TIL (Tumor infiltrating lymphocyte)s within the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Zunyi Medical University, Zunyi, China.
- Department of Immunology, Zunyi Medical University, Zunyi, China immunology@126.com.
ORCID-Profile: Xinsheng Yao
Förderung
- Guizhou Provincial High Level Innovative Talent Fund
- National Natural Science Foundation of China
Zitieren
APA
Peng, Q., Xu, Y., & Yao, X. (2024). scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009376
Vancouver
Peng Q, Xu Y, Yao X. scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009376
BibTeX
@article{Peng2024,
author = {Peng, Qi and Xu, Yuanyuan and Yao, Xinsheng},
title = {scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009376}
}
EUVIMED